BACKGROUND: The effect of practice guidelines and the European Randomised Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal and Ovarian (PLCO) trials on PSA screening practices of primary-care physicians (PCPs) is unknown. METHODS: We conducted a national cross-sectional on-line survey of a random sample of 3010 PCPs from July to August 2010. Participants were queried about their knowledge of prostate cancer, PSA screening guidelines, the ERSPC and PLCO trials, and about their PSA screening practices. Factors associated with PSA screening were identified using multivariable linear regression. RESULTS: A total of 152 (5%) participants opened and 89 completed the on-line survey, yielding a response rate of 58% for those that viewed the invitation. Eighty percent of respondents correctly identified prostate cancer risk factors. In all, 51% and 64% reported that they discuss and order PSA screening for men aged 50-75 years, respectively. Fifty-four percent were most influenced by the US Preventative Services Task Force (USPSTF) guidelines. Also, 21% and 28% of respondents stated that their PSA screening practices were influenced by the ERSPC and PLCO trials, respectively. Medical specialty was the only variable associated with propensity to screen, with family medicine physicians more likely to use PSA screening than internists (β=0.21, P=0.02). CONCLUSIONS: Half of the physicians surveyed did not routinely discuss PSA screening with eligible patients. The impact of the ERSPC and PLCO trials on PSA screening practices was low among US PCPs. USPSTF recommendations for PSA screening continue to be the strongest influence on PCPs' propensity to use PSA screening.
BACKGROUND: The effect of practice guidelines and the European Randomised Screening for Prostate Cancer (ERSPC) and Prostate, Lung, Colorectal and Ovarian (PLCO) trials on PSA screening practices of primary-care physicians (PCPs) is unknown. METHODS: We conducted a national cross-sectional on-line survey of a random sample of 3010 PCPs from July to August 2010. Participants were queried about their knowledge of prostate cancer, PSA screening guidelines, the ERSPC and PLCO trials, and about their PSA screening practices. Factors associated with PSA screening were identified using multivariable linear regression. RESULTS: A total of 152 (5%) participants opened and 89 completed the on-line survey, yielding a response rate of 58% for those that viewed the invitation. Eighty percent of respondents correctly identified prostate cancer risk factors. In all, 51% and 64% reported that they discuss and order PSA screening for men aged 50-75 years, respectively. Fifty-four percent were most influenced by the US Preventative Services Task Force (USPSTF) guidelines. Also, 21% and 28% of respondents stated that their PSA screening practices were influenced by the ERSPC and PLCO trials, respectively. Medical specialty was the only variable associated with propensity to screen, with family medicine physicians more likely to use PSA screening than internists (β=0.21, P=0.02). CONCLUSIONS: Half of the physicians surveyed did not routinely discuss PSA screening with eligible patients. The impact of the ERSPC and PLCO trials on PSA screening practices was low among US PCPs. USPSTF recommendations for PSA screening continue to be the strongest influence on PCPs' propensity to use PSA screening.
Authors: Ingrid J Hall; Sun Hee Rim; Greta M Massetti; Cheryll C Thomas; Jun Li; Lisa C Richardson Journal: Prev Med Date: 2017-08-06 Impact factor: 4.018
Authors: E David Crawford; Matt T Rosenberg; Alan W Partin; Matthew R Cooperberg; Michael Maccini; Stacy Loeb; Curtis A Pettaway; Neal D Shore; Paul Arangua; John Hoenemeyer; Mike Leveridge; Michael Leapman; Peter Pinto; Ian M Thompson; Peter Carroll; James Eastham; Leonard Gomella; Eric A Klein Journal: Urology Date: 2016-07-19 Impact factor: 2.649
Authors: Sun Hee Rim; Ingrid J Hall; Greta M Massetti; Cheryll C Thomas; Jun Li; Lisa C Richardson Journal: J Cancer Educ Date: 2019-08 Impact factor: 2.037
Authors: S Lebentrau; M May; O Maurer; M Schostak; M Lehsnau; T Ecke; S Al-Dumaini; S Hallmann; A M Ahmed; V Braun; A Haferkamp; R M Bauer; C G Stief; D Baumunk; B Hoschke; H-P Braun; C Schäfer; M Hipp; J Maurer; K-P Braun; I Wolff; S Brookman-May; C Gilfrich Journal: Urologe A Date: 2014-05 Impact factor: 0.639